Long-Term Safety and Tolerability of Rivastigmine in Patients With Alzheimer's Disease Switched From Donepezil

Figiel, Gary S.; Koumaras, Barbara; Meng, Xiangyi; Strigas, John; Günay, İbrahim

doi:10.4088/pcc.v10n0503

Cited by 7 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding 4,324 papers after title and abstract review, 264 full‐text articles were examined, and 31 studies were \ included in the systematic review with meta‐analysis (22 longitudinal studies without a control group; 9 cohort studies with a control group) (Supplementary Figure S1). Seven of those were open‐label studies . The 22 longitudinal studies included a total of 34 independent cohorts.…”

Section: Resultsmentioning

confidence: 99%

“…Seven of those were open-label studies. [20][21][22][23][24]33,37 The 22 longitudinal studies included a total of 34 independent cohorts.…”

Section: Resultsmentioning

confidence: 99%

“…Study and participant characteristics are summarized in Supplementary Table S2 (longitudinal studies) and Supplementary Table S3 (cohort studies). Altogether, the 31 studies analyzed represented 258,540 individuals with dementia (15,041 in longitudinal studies, 243,499 in cohort studies) and 2,246,592 controls . Approximately one‐third of the participants had AD, and 66.4% had mixed dementia (Supplementary Tables S2 and S3).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Işık

Soysal

Stubbs

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Seven of those were open-label studies. [20][21][22][23][24]33,37 The 22 longitudinal studies included a total of 34 independent cohorts.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Işık

Soysal

Stubbs

et al. 2018

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…Therefore, memantine has been prescribed alone or in combination with other cognitive drugs such as donepezil (Aricept ® ), rivastigmine (Exelon ® ) and galantamine (Razadyne ® ) as well as anti-psychotic drugs [ 6 , 7 ]. It has been reported that no drug-drug interaction between memantine and donepezil, rivastigmine and galantamine was observed [ 8 , 9 , 10 ]. However, it may interact with other N -methyl- d -aspartate receptor ligands such as dextromethorphan, ketamine and phencyclidine and anti-psychotic drugs such as amantadine and dopamine antagonists [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine

2018

View full text Add to dashboard Cite

A sensitive and simple chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to evaluate memantine in rat plasma. Memantine and propranolol (internal standard) in rat plasma was extracted using a methanol precipitation method. The standard curve value was 0.2–1000 ng/mL and selectivity, linearity, inter-day and intra-day accuracy and precision were within acceptance criteria. Using this validated method, drug-drug interactions between memantine and cimetidine was measured following co-administration of memantine and cimetidine intravenously and orally. Plasma exposure of memantine was increased by 1.6- and 3.0-fold by co-medication with cimetidine intravenously and orally, respectively. It suggested that the drug interaction occurred during the gut absorption process, which was consistent with the results showing that the intestinal permeability of memantine in the presence of cimetidine was 3.2-fold greater than that of memantine alone. Inhibition of cimetidine on hepatic elimination of memantine rather than renal excretion was also attributed to the drug-drug interaction between memantine and cimetidine, which explained the decreased clearance of memantine by co-medication with cimetidine. In conclusion, the newly developed simple and sensitive LC-MS/MS analytical method was applied to investigate the pharmacokinetic drug-drug interactions of memantine. Plasma exposure of memantine by co-administration with cimetidine was increased because of its enhanced intestinal permeability and the decreased metabolic activity of memantine.

show abstract

“…The mean drugplacebo differences, at end point for the groups receiving 5 mg/d and 10 mg/d of donepezil hydrochloride were, respectively, 2.5 and 3.1 units for the ADAS-cog (11,12). Results from a Cochrane review suggest that donepezil results in statistically significant improvements for both 5 and 10 mg/day at 24 weeks compared with placebo on the ADAS-cog, with a 2.01 point and a 2.80 point reduction, respectively (9).…”

Section: Donepezilmentioning

confidence: 99%

Medications used in dementia: a review of evidence

Suraweera

Hanwella²,

Silva

2015

Sri Lanka J. Psyc.

View full text Add to dashboard Cite

Medications used in dementia: a review of evidence psychological symptoms of dementia (BPSD), and has also being considered for the treatment of dementias of lesser severity.Evidence also supports the use of AChE inhibitors in vascular dementia and dementia due to Parkinson's disease (PDD). But evidence regarding efficacy in dementia of Lewy Body (DLB) is not very strong.Antipsychotics can be used for the management of BPSD if other measures fail, keeping in mind the black box warning for the risk of stroke. The use of antidepressants and mood stabilisers are limited by the lack of strong evidence. ConclusionThe current evidence supports the use of cholinesterase inhibitors and memantine in patients with Alzheimer's dementia, vascular dementia and PDD, with a positive impact on global assessment, cognitive function, behavioural disturbance and activities of daily living rating scales. The effect in DLB remains unclear. SL J Psychiatry 2015; 6(2): 3-8 BackgroundDementia is an acquired global impairment of intellect, memory and personality, without impairment of consciousness. It is usually progressive in nature. The management of dementia is mainly two faceted; pharmacological and non-pharmacological. AimsTo review the evidence regarding the efficacy of cholinesterase inhibitors, memantine and antipsychotics, in the treatment of dementia. MethodsWe searched ALOIS, Cochrane database, PubMed, Scopus and Google scholar using key words; dementia, cognitive enhancers, cholinesterase inhibitors and memantine as individual words for relevant review articles. ResultsThere is evidence of efficacy of donepezil, rivastigmine and galantamine in mild to moderate Alzheimer's dementia (AD). Evidence also suggests that memantine has efficacy in moderate to severe AD. Further, memantine may benefit behavioural and

show abstract

Long-Term Safety and Tolerability of Rivastigmine in Patients With Alzheimer's Disease Switched From Donepezil

Abstract: For patients not tolerating or not responding to donepezil, treatment with rivastigmine was safe and well tolerated for at least 52 weeks.

Cited by 7 publications

References 23 publications

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine

Medications used in dementia: a review of evidence

Contact Info

Product

Resources

About